Chemotherapy and PD-1/PD-L1 Inhibitor Combinations for TKI-Resistant EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis
ESMO Open 2024 Aug 20;9(9)103660, Z Piotrowska, BY Yeap, JF GainorFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.